Printer Friendly

VERTEX PHARMACEUTICALS ANNOUNCES EXECUTIVE PROMOTIONS

 VERTEX PHARMACEUTICALS ANNOUNCES EXECUTIVE PROMOTIONS
 CAMBRIDGE, Mass., May 21 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that Richard Aldrich has been named to the newly created position of chief business officer and Keith Ehrlich has been appointed treasurer of the company.
 In his new position, Aldrich will have responsibility for all of Vertex's business development, marketing, finance, and operational activities. Aldrich has served as vice president of business development and marketing since he joined Vertex in 1989. Ehrlich adds the post of treasurer to his current responsibilities as director of finance.
 "We are pleased to announce these promotions," said Joshua Boger, president and CEO of Vertex. "Both Rich and Keith have made important contributions to Vertex. Their new responsibilities reflect those accomplishments as well as the expanding business activities of the company."
 Vertex is a leader in the use of structure-based rational drug design, a scientific approach to drug discovery which uses atomic level information to design synthetic compounds that interact with protein targets involved in disease processes. Vertex is using advanced techniques of biology, chemistry and biophysics to create novel, small molecule compounds that the company plans to develop as orally deliverable drugs to treat major human diseases. Vertex is concentrating on the development of drugs in the areas of immunology, inflammation and antiviral therapy.
 -0- 5/21/92
 /CONTACT: Rich Aldrich, vice president of Vertex Pharmaceuticals, 617-576-3111, or Robert Gottlieb of Feinstein Partners, 617-577-8110, for Vertex Pharmaceuticals/
 (VRTX) CO: Vertex Pharmaceuticals Incorporated ST: Massachusetts IN: MTC SU: PER


SH -- NE006 -- 2739 05/21/92 10:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 21, 1992
Words:260
Previous Article:COOPER INDUSTRIES REPORTS FIRST-QUARTER NET INCOME UP 10 PERCENT
Next Article:AMAX GOLD EXPECTED TO EXERCISE HAILE PROPERTY OPTION
Topics:


Related Articles
VERTEX AND KISSEI PHARMACEUTICAL SIGN $20 MILLION AGREEMENT TO DEVELOP NOVEL DRUGS TO TREAT HIV INFECTION AND AIDS
VERTEX PHARMACEUTICALS REPORTS 1993 FIRST QUARTER RESULTS
VICKI L. SATO, PH.D., PROMOTED TO SENIOR VICE PRESIDENT, RESEARCH AND DEVELOPMENT AT VERTEX PHARMACEUTICALS
Dr. Joshua Boger Named Vertex Pharmaceuticals' Chairman of the Board of Directors
Vertex and Eli Lilly Form Strategic Alliance to Develop Drugs to Treat Hepatitis C Infection
John J. Alam, M.D. Joins Vertex as Vice President, Clinical Development
Kissei Pharmaceutical Files for Approval of HIV Protease Inhibitor in Japan.
Hoechst Marion Roussel and Vertex Expand Agreement to Develop Novel Anti-Inflammatory Compounds.
Vertex Announces Hart-Scott-Rodino Clearance for Expanded Agreement With Hoechst Marion Roussel.
Vertex Pharmaceuticals Secures Hepatitis C License Agreement from Chiron Corporation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters